Instrument Inactif

Communiqués Incannex Healthcare Australian S.E.

Actions

IHL

AU000000IHL8

Recherche biotechnologique et médicale

Communiqués

25/06	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	AQ
10/06	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility	AQ
09/06	Incannex Announces Initiation of Research Coverage by Alliance Global Partners	AQ
14/05	Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea	AQ
12/05	Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development	AQ
22/04	Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness	AQ
27/03	Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position	AQ
25/03	Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research	AQ
18/03	Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development	AQ
17/03	Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
12/03	Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
12/03	Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes	AQ
25/02	Incannex Announces Reverse Stock Split	AQ
19/02	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026	NE
29/01	Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board	AQ
22/01	Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program	AQ
15/01	Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards	AQ
14/01	Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026	AQ
03/12	Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)	AQ
20/11	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026	NE
30/10/25	Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus	AQ
22/10/25	Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	AQ
26/08/25	Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder	AQ
22/08/25	Incannex Healthcare Authorizes $20 Million Share Repurchase Program	AQ
19/08/25	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update	NE